| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Insider activity in IONS over the last quarter tilts toward selling: insiders offloaded a net 196,094 shares worth roughly $15.4M.
Classified under Biotechnology (Health Care sector), IONS's insider flows are most useful compared with peers in the same group.
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| Dir | 156.0K | $8.82M | - | |
| CEO | 99.9K | $5.65M | - | |
| CFO | 82.7K | $4.68M | - | |
| VP | 74.4K | $4.21M | - | |
| VP | 69.7K | $3.94M | - |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| May 3, 2024 | Klein Joseph III60 | Director | Sell | 6,000 | $42.71 | $256,276.57 | -29.5% | +22.3% | -21.9% | |
| Apr 16, 2024 | Baroldi Joseph53 | EVP, Chief Business Officer | Sale+OE | 4,006 | $41.60 | $166,640.79 | -16.9% | +14.5% | -31.8% | |
| Apr 16, 2024 | Birchler Brian55 | EVP, Corp And Development Ops | Sale+OE | 905 | $41.66 | $37,698.23 | -1.9% | +14.5% | -31.8% | |
| Feb 16, 2024 | Monia Brett P60 | Chief Executive Officer | Sell | 387 | $44.49 | $17,218.56 | -0.2% | -15.3% | -30.1% | |
| Feb 2, 2024 | O'Neil Patrick R.57 | EVP CLO &General Counsel | Sell | 1,961 | $49.67 | $97,410.32 | -3.9% | -13.4% | -35.9% | |
| Feb 2, 2024 | Hougen Elizabeth L55 | EVP, Finance &CFO | Sell | 2,125 | $49.54 | $105,272.29 | -2.2% | -13.4% | -35.9% | |
| Feb 2, 2024 | Geary Richard S65 | EVP, Chief Development Officer | Sell | 1,961 | $50.04 | $98,134.91 | -2.2% | -13.4% | -35.9% | |
| Feb 2, 2024 | Cadoret-Manier Onaiza53 | EVP, Chf Gl Pdt Str &Oper Ofc | Sell | 2,125 | $49.60 | $105,404.25 | -5.6% | -13.4% | -35.9% | |
| Feb 2, 2024 | Bennett C Frank64 | EVP, Chief Scientific Officer | Sell | 1,853 | $49.52 | $91,752.41 | -2.3% | -13.4% | -35.9% | |
| Feb 2, 2024 | Schneider Eugene64 | EVP, Chf Clinical Develop Ofcr | Sell | 2,071 | $49.59 | $102,700.89 | -4.0% | -13.4% | -35.9% |